Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KCNH3 | Q9ULD8 | 11/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TXN | P10599 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300314 | 0.85 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2KCNH3MEN1 | |
| SCHEMBL9762820 | 0.84 | TAAR1 (0.56) | RAB9ANPC1SMN1; SMN2KCNH3MEN1 | |
| SCHEMBL6957616 | 0.80 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2KCNH3MEN1 | |
| SCHEMBL6964614 | 0.76 | TXN (0.54) | RAB9ANPC1SMN1; SMN2KCNH3MEN1 | |
| SCHEMBL12485120 | 0.74 | TAAR1 (0.72) | RAB9ANPC1SMN1; SMN2KCNH3MEN1 | |
| SCHEMBL12484610 | 0.74 | TAAR1 (0.51) | RAB9ANPC1KCNH3MEN1KMT2A | |
| SCHEMBL12483299 | 0.73 | KCNH3 (0.47) | RAB9ANPC1KCNH3TXN | |
| SCHEMBL8256589 | 0.72 | GAA (0.43) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9763442 | 0.72 | KCNH3 (0.44) | RAB9ANPC1SMN1; SMN2KCNH3MEN1 | |
| SCHEMBL9499365 | 0.72 | IGF1R (0.45) | RAB9ANPC1SMN1; SMN2KCNH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| US-8653109-B2 | Substituted bipyridine derivatives and their use as adenosine receptor ligands | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653109-B2 | Substituted bipyridine derivatives and their use as adenosine receptor ligands | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653109-B2 | Substituted bipyridine derivatives and their use as adenosine receptor ligands | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008028590-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | RAB9A 2792/4885NPC1 1639/4885SMN1; SMN2 4426/4885 |
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | RAB9A 2792/4885NPC1 1639/4885SMN1; SMN2 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.